Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 86.6% in March

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 7,237 shares, a decline of 86.6% from the February 26th total of 53,938 shares. Based on an average daily trading volume, of 630,250 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 630,250 shares, the short-interest ratio is presently 0.0 days.

Oncotelic Therapeutics Price Performance

Shares of OTLC traded up $0.00 during trading hours on Tuesday, reaching $0.04. 673,912 shares of the company traded hands, compared to its average volume of 314,676. The business has a fifty day moving average price of $0.06 and a 200-day moving average price of $0.07. Oncotelic Therapeutics has a 12-month low of $0.02 and a 12-month high of $0.11.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.